Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Primary biliary cholangitis epidemiology
- Epidemiology
- The prevalence of PBC may be on the rise
- Lower female:male sex rate
- Slow development in rare diseases
- PBC history
- PBC is autoimmune disease
- The use of URSO and liver transplantation
- 2016
- It all starts with the breaking of tolerance
- Conditions that threaten tolerance
- T-reg defects could be involved
- The effect of super enhancers in PBC
- Susceptibility loci associated PBC
- The autoantigen
- Autoantigen mimics
- Tolerance and xenobiotics
- Mistakes in self-recognition
- Autoantigen and bacterial PDC-E2
- Immune damage
- After breaking tolerance…what happens?
- Expansion of PDC-E2 auto reactive cells
- Autoreactivity and immune regulation
- Why bile ducts?
- The inflamed bile duct is in dual jeopardy
- Bile ducts as targets
- Employing new treatment strategies
- PDC-E2 reactive antibodies
- Different therapeutic strategies
- PBC cytokines
- Harnessing the immune system before pathology
- Where to intervene?
- Pathogenesis of PBC
- Immunotherapy where are we?
- Where to focus?
- Benefits of early diagnosis
- New hope for major improvements in PBC
Topics Covered
- Primary biliary cholangitis epidemiology
- The prevalence of PBC may be on the rise
- PBC is autoimmune disease
- Tolerance and xenobiotics
- Immune damage
- Autoreactivity and immune regulation
- Bile ducts as targets
- Employing new treatment strategies
- PDC-E2 reactive antibodies
- Pathogenesis of PBC
- Benefits of early diagnosis
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gershwin, M.E. (2018, November 4). What causes primary biliary cholangitis? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VEMW5497.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. M. Eric Gershwin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
So, my name is Eric Gershwin.
I'm professor of medicine at UC Davis,
and I've been studying autoimmunity,
especially autoimmunity involving both the liver
and the bile ducts for almost my entire professional life.
And what I'd like to do in the next 45 minutes or so,
are to talk specifically about autoimmune diseases of the liver,
particularly what PBC is,
which is an autoimmune disease,
which affects a female population,
and destroys the small bile ducts.
0:36
And so, I'll start by basically exploring issues that I
know and issues that I hope to know about what PBC is.
I think it's important to start off with the premise that
the prognosis and the outlook for patients with PBC is getting better.
And I mentioned that because if we go back to the old books of the 1970s,
even the 1980s, the prognosis seemed awful,
and for a large number of reasons,
some of which we'll discuss it is certainly the case that the outlook is getting better.
But, it isn't disappearing and if anything and I'll show you some epidemiology,
the incidence is actually increasing as perhaps it is with all of
autoimmunity and all of the more than a 100 different types of autoimmune diseases.
So, let's talk about the epidemiology.
As you could imagine,
almost all the data is coming from the Western world and there's
an enormous range on the incidence and the prevalence of PBC.